Editor’s Special Episode: ASCO 2025 Highlights in AML with Dr. Amir Fathi

In this Editor’s Special Episode of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucekr sits down with Amir Fathi, MD, of Massachusetts General Hospital, to discuss key updates in the treatment landscape for acute myeloid leukemia (AML) presented at the ASCO 2025 Annual Meeting. The conversation begins with a deep dive into a notable phase 2 study investigating an all-oral regimen of decitabine and cedazuridine plus venetoclax for patients with newly-diagnosed AML who are ineligible for intensive induction therapy.

Dr. Fathi highlights the potential for oral regimens to offer patients more convenient, outpatient-friendly options without compromising efficacy. He explains the importance of replicating the promising results of lower-intensity regimens in other settings and clinical sites to better understand their broader applicability. The conversation also touches on shifting treatment paradigms toward doublet and triplet regimens that combine hypomethylating agents with targeted therapies such as FLT3 inhibitors, IDH inhibitors, and menin inhibitors.

Looking to the future, Dr. Fathi expresses cautious optimism about novel agents addressing hard-to-treat AML subgroups, such as those with TP53 mutations or progression after venetoclax-based therapy. He also shares his excitement around upcoming phase 3 trials, including studies on menin inhibitors and the Quantum Wild trial evaluating quizartinib in FLT3 wild-type AML.